These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37252843)

  • 1. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma.
    Kim S; Carvajal R; Kim M; Yang HW
    Cell Rep; 2023 Jun; 42(6):112570. PubMed ID: 37252843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
    Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
    Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
    Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
    Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
    Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
    Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
    Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
    Tiago M; Capparelli C; Erkes DA; Purwin TJ; Heilman SA; Berger AC; Davies MA; Aplin AE
    Br J Cancer; 2020 Mar; 122(6):789-800. PubMed ID: 31932756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
    Girotti MR; Lopes F; Preece N; Niculescu-Duvaz D; Zambon A; Davies L; Whittaker S; Saturno G; Viros A; Pedersen M; Suijkerbuijk BM; Menard D; McLeary R; Johnson L; Fish L; Ejiama S; Sanchez-Laorden B; Hohloch J; Carragher N; Macleod K; Ashton G; Marusiak AA; Fusi A; Brognard J; Frame M; Lorigan P; Marais R; Springer C
    Cancer Cell; 2015 Jan; 27(1):85-96. PubMed ID: 25500121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.
    Tripathi R; Liu Z; Jain A; Lyon A; Meeks C; Richards D; Liu J; He D; Wang C; Nespi M; Rymar A; Wang P; Wilson M; Plattner R
    Nat Commun; 2020 Oct; 11(1):5463. PubMed ID: 33122628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
    Gerosa L; Chidley C; Fröhlich F; Sanchez G; Lim SK; Muhlich J; Chen JY; Vallabhaneni S; Baker GJ; Schapiro D; Atanasova MI; Chylek LA; Shi T; Yi L; Nicora CD; Claas A; Ng TSC; Kohler RH; Lauffenburger DA; Weissleder R; Miller MA; Qian WJ; Wiley HS; Sorger PK
    Cell Syst; 2020 Nov; 11(5):478-494.e9. PubMed ID: 33113355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.